Han KY, Wang CM, Du CB, Qiao J, Wang YL, Lv LZ. Treatment outcomes and cognitive function following electroconvulsive therapy in patients with severe depression. World J Psychiatry 2023; 13(11): 949-957 [PMID: 38073900 DOI: 10.5498/wjp.v13.i11.949]
Corresponding Author of This Article
Li-Zhao Lv, MSc, Attending Doctor, Department of Neurology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, Hebei Province, China. 18633889992@163.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Nov 19, 2023; 13(11): 949-957 Published online Nov 19, 2023. doi: 10.5498/wjp.v13.i11.949
Treatment outcomes and cognitive function following electroconvulsive therapy in patients with severe depression
Ke-Yan Han, Chao-Min Wang, Chong-Bo Du, Jun Qiao, Yong-Liang Wang, Li-Zhao Lv
Ke-Yan Han, Chao-Min Wang, Chong-Bo Du, Jun Qiao, Yong-Liang Wang, Li-Zhao Lv, Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China
Author contributions: Han KY, Wang CM, and Lv LZ were responsible for the study conception and design; Du CB and Qiao J provided administrative support; Han KY and Lv LZ provided the study materials and patients; Wang YL and Qiao J conducted data collection; Han KY and Lv LZ conducted data analysis and interpretation; All authors contributed to the manuscript writing process and granted final approval for the manuscript.
Supported byHebei Province 2018 Medical Science Research Key Discipline Programs, No. 20180214.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the First Hospital of Hebei Medical University.
Informed consent statement: All study participants, or their legal guardian, provided written consent prior to study enrollment.
Conflict-of-interest statement: The authors of this manuscript having no conflicts of interest to disclose.
Data sharing statement: There is no additional data available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Zhao Lv, MSc, Attending Doctor, Department of Neurology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, Hebei Province, China. 18633889992@163.com
Received: September 13, 2023 Peer-review started: September 13, 2023 First decision: September 28, 2023 Revised: October 7, 2023 Accepted: October 28, 2023 Article in press: October 28, 2023 Published online: November 19, 2023 Processing time: 65 Days and 0.7 Hours
Core Tip
Core Tip: Electroconvulsive therapy (ECT) is more efficient and safer in treating severe major depressive disorder (MDD) compared to medication and/or therapy. Here, ECT led to more pronounced improvements in depressive symptoms, quality of life, and cognitive function than non-ECT treatments. Additionally, ECT affected biomarkers related to neuroplasticity (brain-derived neurotrophic factor) and inflammation (interleukin-6). These findings highlight the potential of ECT as a therapeutic approach for individuals with severe MDD who do not respond to conventional treatments. By providing evidence of its beneficial outcomes, this study aimed to address the stigmatization surrounding ECT and facilitate its broader adoption in clinical practice.